Use of transgenic cell lines in mechanistic studies of drug metabolism

Toxicology in Vitro

Volumn 13, Issue 4-5, 1999, Pages 625-632

  Gasser, R ^a   Funk, C ^a   Matzinger, P ^a   Klemisch, W ^a   Viger Chougnet, A ^a  

^a Preclinical Research   (Switzerland)

Author keywords

Cytochrome P450; Recombinant enzyme

Indexed keywords

CYTOCHROME P450; DRUG; RECOMBINANT ENZYME;

BIOTRANSFORMATION; CONFERENCE PAPER; DRUG DEVELOPMENT; HUMAN; METABOLISM; MICROSOME; NONHUMAN; TRANSGENE;

EID: 0032839439     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(99)00035-1     Document Type: Conference Paper

References (31)

1. Bensoussan C., Delaforge M., Mansuy D. Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology. 49:1995;591-602.
2. Bergstrom R.F., Peyton A.L., Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapy. 51:1992;239-248.
3. Birkett D.J., MacKenzie P.I., Veronese M.E., Miners J.O. In vitro approaches can predict human drug metabolism. Trends in Pharmaceutical Science. 14:1993;292-294.
4. Brosen K., Hansen J.G., Nielsen K.K., Sindrup S.H., Gram L.F. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology. 44:1993;349-355.
5. Chen L., Buters J.T., Hardwick J.P., Tamura S., Penman B.W., Gonzalez F.J., Crespi C.L. Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. Drug Metabolism and Disposition. 25:1997;399-405.
6. Cohen S.D., Pumford N.R., Khairallah E.A., Boekelheide K., Pohl L., Amouzadeh H.R., Hinson J.A. Contemporary issues in toxicology: Selective protein covalent binding and target organ toxicity. Toxicology and Applied Pharmacology. 143:1997;1-12.
7. Crespi C.L., Langenbach R., Penman B.W. Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology. 82:1993;89-104.
8. Crespi C.L., Miller V.P., Penman B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical Biochemistry. 248:1997;188-190.
9. Crespi C.L., Penman B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advances in Pharmacology. 43:1997;171-188.
10. Franklin M.R. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in Enzymology. 206:1991;559-573.
11. Franklin M.R. Inhibition of mixed function oxidations by substrates forming reduced cytochrome P450 metabolic-intermediate complexes. Pharmacology and Therapeutics. 2:1977;227-245.
12. Gonzalez F.J., Aoyama T., Gelboin H.V. Expression of mammalian cytochrome P450 using vaccinia virus. Methods in Enzymology. 206:1991;85-92.
13. Gram L.F., Brosen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. British Journal of Clinical Pharmacology. 35:1993;649-652.
14. Gram L.F., Guentert T.W., Grange S., Vistisen K., Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clinical Pharmacology and Therapeutics. 57:1995;670-677.
15. Guengerich F.P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chemical Research in Toxicology. 3:1990;363-371.
16. Jauch R., Griesser E., Oesterhelt G., Arnold W., Meister W., Ziegler W.H., Guentert T.W. Biotransformation of moclobemide in humans. Acta Psychiatrica Scandinavica. Suppl. 360:1990;87-90.
17. Lopez Garcia M.P., Dansette P.M., Valadon P., Amar C., Beaune P.H., Guengerich F.P., Mansuy D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. European Journal of Biochemistry. 213:1993;223-232.
18. Nice E.C., O'Hare M.J. Selective effects of reversed phase column packings in HPLC of steroids. Journal of Chromatography. 166:1978;263-267.
19. Obach R.S. The importance of nonspecific binding in In vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metabolism and Disposition. 24:1996;1047-1049.
20. Park B.K., Pirmohamed M., Kitteringham N.R. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chemical Research in Toxicology. 11:1998;969-988.
21. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clinical Pharmacokinetics. 32:(Suppl. 1):1997;1-21.
22. Pritchard M.P., Glancey M.J., Blake J.A., Gilham D.E., Burchell B., Wolf C.R., Friedberg T. Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics. 8:1998;33-42.
23. Pritchard M.P., Ossetian R., Li D.N., Henderson C.J., Burchell B., Wolf C.R., Friedberg T. A general strategy for the expression of recombinant human cytochrome P450 s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Archives of Biochemistry and Biophysics. 345:1997;342-354.
24. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapy. 270:1994;414-423.
25. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Miners J.O. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P4501A1 and 1A2. Pharmacogenetics. 4:1994;281-284.
26. Triggle D.J. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a calcium antagonist. American Journal of Cardiology. 78:1996;7-12.
27. Tucker G.T. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. International Journal of Clinical Pharmacology, Therapeutics and Toxicology. 30:1992;550-553.
28. Valles B., Coassolo P., De Sousa G., Aubert C., Rahmani R. In vitro hepatic biotransformation of moclobemide (Ro 11-1163) in man and rat. Xenobiotica. 23:1993;1101-1111.
29. van der Hoeven T.A., Coon M. Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphate cytochrome P450 reductase from rabbit liver microsomes. Journal of Biological Chemistry. 249:1974;6302-6310.
30. Von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics. 268:1994;1278-1283.
31. von Rosensteil N.A., Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety. 13:1995;105-122.